Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for Prevention of CINV in Multiple Myeloma
NCT00571168Phase 3Unknown
- Sponsor
- Heidelberg University
- Start
- Jul 2005
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Aprepitant + Standard Therapy with Placebo + Standard Therapy (2 arms). Primary endpoint: Overall complete response. Status: unknown.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00571168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571168.